Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
305.8 USD | +1.59% | -0.01% | +6.17% |
05-28 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
05-28 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
Evolution of the average Target Price on Amgen Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Amgen Inc.
HSBC | |
Redburn Atlantic | |
Mizuho Securities | |
UBS | |
Deutsche Bank Securities | |
William Blair & Co. | |
Leerink Partners | |
Barclays | |
Morgan Stanley | |
RBC Capital Markets | |
BMO Capital | |
Goldman Sachs | |
TD Cowen | |
Oppenheimer | |
Baird | |
Daiwa Securities | |
Truist Securities | |
Argus | |
Jefferies & Co. | |
Credit Suisse | |
DA Davidson | |
Piper Sandler | |
Wells Fargo Securities | |
SVB Securities LLC | |
Cowen | |
Atlantic Equities | |
BofA Securities | |
SVB Leerink | |
JPMORGAN | Cory Kasimov |
RBC | Kennen Mackay |
EPS Revisions
- Stock Market
- Equities
- AMGN Stock
- Consensus Amgen Inc.